The effect of somatostatin for treatment of post hepatectomy liver failure (PHLF)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CRIS

Registry ID

KCT0001977

Enrollment

Registered

2016-07-22

Start date

2016-02-15

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : We administrate somatostatin at a rate of 3.5ug/kg/hour to PHLF patients (prothrombin time 2.9mg/dl after liver resection) until recovery from liver failure.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with PHLF without regard primary disease. 2. Ability to provide written informed consent

Exclusion criteria

Exclusion criteria: 1. Concomitant surgery for another intraabdominal organs. 2. Severe renal disease requiring dialysis. 3. Patients with coagulation disorders or taking warfarin. 4. Immunosuppressed patients or the patients with autoimmune disorders. 5. Women with pregnant, breast-feeding. 6. Hypersensitivity to somatostatin. 7. Patients treated with other investigational product within 30 days at the consents are obtained. 8. Patients with a significantly reduced cognitive abilities. 9. Not eligible to participate for study at the discretion of investigator.

Design outcomes

Primary

Measure	Time frame
in hospital mortality	—

Secondary

Measure	Time frame
Complication rate;Time to recovery from PHLF (days)	—

Countries

Korea, Republic of

Contacts

Public ContactJae Hyun Han

Korea University

Outcome results